Table 4 Tools for assigning the pathogenic likelihood or functional impact of variants.
BaylorSeq | BCM | Duke/Columbia | Harvard | Miami | NIH | PacificNW | Stanford | UCLA | Utah | Vanderbilt | WUSTL | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cross-species conservation scores | ||||||||||||
GERP++: Genomic Evolutionary Rate Profiling | ● | ● | ● | ● | ● | |||||||
PhastCons | ● | ● | ● | |||||||||
Predicted functionality or pathogenicity | ||||||||||||
PolyPhen-2 | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ||
SIFT | ● | ● | ● | ● | ● | ● | ● | ● | ● | |||
MutationTaster | ● | ● | ● | ● | ||||||||
MVP: missense variant pathogenicity | ● | |||||||||||
ReMM: regulatory Mendelian mutation | ● | |||||||||||
Ensemble pathogenicity predictors | ||||||||||||
CADD: Combined Annotation Dependent Depletion | ● | ● | ● | ● | ● | ● | ● | ● | ||||
REVEL: Rare Exome Variant Ensemble Learner | ● | ● | ● | ● | ● | ● | ● | ● | ||||
DANN: Deep Neural Net version of CADD | ● | ● | ||||||||||
M-CAP: Mendelian Clinically Applicable Pathogenicity | ● | ● | ||||||||||
DOMINO: Dominant Disorder Associated Genesa | ● | |||||||||||
Eigen | ● | |||||||||||
Predicted splice- or expression-altering effect | ||||||||||||
SpliceAI | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ||
GTEx: Genotype-Tissue Expression | ● | ● | ● | ● | ||||||||
SpliceRegion annotations from VEP | ● | ● | ● | ● | ||||||||
dbscSNV (splicing consensus SNVs) | ● | ● | ● | |||||||||
Human Splicing Factor | ● | ● | ||||||||||
MMSplice: Modular modeling of splicing | ● | ● | ||||||||||
MaxEntScan | ● | ● | ||||||||||
TraP: Transcript-inferred Pathogenicity | ● | |||||||||||